Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. NWANKWO (Fulham, United Kingdom), D. Armstrong-James (Fulham, United Kingdom), A. Shah (Fulham, United Kingdom). Use of Isavuconazole MIC to guide dosing in the management of Aspergillosis in patients with pulmonary disease. 2309

Member's Comments

No comment yet.

Related content which might interest you: Antibiotic treatment in pneumonia and chronic obstructive pulmonary disease – adherence to guidelines in an English teaching hospital Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management Source: Guideline 2016 Year: 2016 Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management Source: Eur Respir J 2016; 47: 45-68 Year: 2016 Treatment outcome of combination antibiotic therapy including clarithromycin for Mycobacterium avium complex pulmonary disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 Perspectives on antibiotic treatment of NTM pulmonary disease Source: Eur Respir Monogr 2017; 75: 245-252 Year: 2017 Clinical efficacy and safety of micafungin in patients with pulmonary aspergillosis Source: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006 Antibiotic resistance in ambulatory patients with chronic obstructive pulmonary disease–clinical signs Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Treatment of chronic pulmonary aspergillosis by voriconazole compared with micafungin Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus Year: 2009 Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD Source: Eur Respir J 2009; 34: 1066-1071 Year: 2009 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients Source: Eur Respir J 2001 Jan 01;19(4):743-755 Year: 2002 Efficacy of moxifloxacin instead of ethambutol in the intensive phase of therapy in newly diagnosed pulmonary TB Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Rational use and stewardship of antibiotics in pediatric respiratory disease Source: ERS Courses: Paediatric respiratory infections Year: 2019 Clinical features of chronic pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Invasive pulmonary aspergillosis: What is the role of surgery in the voriconazole era? Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Antibiotic treatment and prophylaxis Source: Annual Congress 2006 - Infections and chronic obstructive lung diseases Year: 2006